C12N 9/6424
Serine endopeptidases
Official title: {Serine endopeptidases (3.4.21)}
C12N9/6424 (Serine endopeptidases) appears on 2,593 US grants and 2,840 published applications in this corpus.
Search patents in C12N- Granted patents
- 2,593
- Published applications
- 2,840
- Assignees
- 1,238
- Inventors
- 5,456
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 8 | 0 |
| 1977 | 8 | 0 |
| 1978 | 10 | 0 |
| 1979 | 6 | 0 |
| 1980 | 5 | 0 |
| 1981 | 18 | 0 |
| 1982 | 14 | 0 |
| 1983 | 11 | 0 |
| 1984 | 14 | 0 |
| 1985 | 22 | 0 |
| 1986 | 11 | 0 |
| 1987 | 13 | 0 |
| 1988 | 20 | 0 |
| 1989 | 16 | 0 |
| 1990 | 39 | 0 |
| 1991 | 44 | 0 |
| 1992 | 59 | 0 |
| 1993 | 55 | 0 |
| 1994 | 48 | 0 |
| 1995 | 43 | 0 |
| 1996 | 52 | 0 |
| 1997 | 75 | 0 |
| 1998 | 115 | 0 |
| 1999 | 104 | 0 |
| 2000 | 97 | 0 |
| 2001 | 84 | 11 |
| 2002 | 61 | 119 |
| 2003 | 64 | 295 |
| 2004 | 50 | 138 |
| 2005 | 51 | 103 |
| 2006 | 77 | 123 |
| 2007 | 103 | 76 |
| 2008 | 69 | 87 |
| 2009 | 45 | 123 |
| 2010 | 66 | 87 |
| 2011 | 57 | 83 |
| 2012 | 55 | 86 |
| 2013 | 48 | 87 |
| 2014 | 56 | 121 |
| 2015 | 68 | 108 |
| 2016 | 73 | 130 |
| 2017 | 75 | 110 |
| 2018 | 64 | 103 |
| 2019 | 77 | 130 |
| 2020 | 81 | 125 |
| 2021 | 91 | 134 |
| 2022 | 63 | 94 |
| 2023 | 60 | 104 |
| 2024 | 57 | 109 |
| 2025 | 59 | 95 |
| 2026 | 32 | 59 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 9/6456Plasminogen activators568
- C12N 9/644Coagulation factor ixa397
- C12N 9/6437Coagulation factor viia245
- C12N 9/6429Thrombin213
- C12N 9/647Blood coagulation factors not provided for in a preceding group or according163
- C12N 9/6435Plasmin , i.e. fibrinolysin155
- C12N 9/6445Kallikreins148
- C12N 9/6432Coagulation factor xa136
Recent patents
- Method for analyzing protein29 Sep 2026US 12,747,465 B2Hitachi, Ltd.
- Complement factor I and complement factor I cofactor, vectors encoding therefor and therapeutic use8 Sep 2026US 12,728,171 B2Novartis Pharmaceuticals UK Limited
- Inter-application workflow performance analytics18 Aug 2026US 12,711,443 B2Box, Inc.
- Optimized synthetic consensus immunogenic compositions targeting fibroblast activation protein4 Aug 2026US 12,697,298 B2The Trustees of the University of Pennsylvania
- Acellular dermal matrix for skin and surgical reconstruction and methods of making same28 Jul 2026US 12,691,202 B1Humabiologics, Inc.
- Method for the Production of Pharmaceutically Active Recombinant Human Low Molecular Weight Urokinase8 Oct 2026US 2026/0308654 A1Cerbios-Pharma SA
- Antimicrobial defensin peptide folding variants1 Oct 2026US 2026/0297145 A1Donald Danforth Plant Science Center
- Antimicrobial nodule-specific cysteine-rich peptide folding variants1 Oct 2026US 2026/0297146 A1Donald Danforth Plant Science Center
- Engineered cell preparations for treatment of hemophilia24 Sep 2026US 2026/0286298 A1Be Biopharma, Inc.
- Vector production24 Sep 2026US 2026/0286391 A1Fondazione Telethon Ets
Most cited
By later US patents
- Plasminogen activator derivatives616US 4,640,835 ANippon Chemiphar Co., Ltd. · 1987
- Isolation of exogenous recombinant proteins from the milk of transgenic mammals500US 4,873,316 ABiogen, Inc. · 1989
- Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor346US 7,906,111 B2The Trustees of the University of Pennsylvania · 2011
- Engineered nucleic acids encoding a modified erythropoietin and their expression312US 8,710,200 B2Moderna Therapeutics, Inc. · 2014
- Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor288US 7,282,199 B2The Trustees of the University of Pennsylvania · 2007